What are the off‑label uses of levetiracetam (Keppra)?

Off-Label Uses of Levetiracetam (Keppra)

Levetiracetam has demonstrated efficacy as an off-label treatment for refractory status epilepticus, with multiple studies showing seizure cessation rates of 67-73% when used after benzodiazepine failure, though definitive prospective randomized trials are still needed. 1

Primary Off-Label Use: Status Epilepticus

Evidence for Status Epilepticus Treatment

The most robust off-label use of levetiracetam is for benzodiazepine-refractory status epilepticus. The 2014 American Academy of Neurology/American Epilepsy Society guidelines provide Class III evidence supporting this indication 1:

• Dosing: 30 mg/kg IV load delivered at 5 mg/kg per minute (up to 2,500-4,500 mg) 1
• Efficacy: Seizure cessation rates range from 67-89% across multiple studies
  • Tripathi et al: 73% efficacy (comparable to valproate at 68%) 1
  • Ruegg et al: 67% cessation rate in 24 patients 1
  • Fattouch et al: 78% seizure cessation with 1,500 mg load 1
  • Larger retrospective studies: 44-73% efficacy within 3 minutes to 24 hours 1

Safety Profile in Status Epilepticus

Levetiracetam demonstrates a favorable safety profile compared to traditional agents, with minimal adverse effects:

• No serious adverse events attributable to infusion 1
• Rare side effects: nausea, transient transaminitis (individual cases) 1
• No hypotension or respiratory depression (unlike phenytoin and barbiturates) 1
• Safe for rapid administration as undiluted IV push, even at high doses (2,500-4,500 mg) 2, 3

Clinical Algorithm for Status Epilepticus

1. First-line: Benzodiazepines (lorazepam)
2. Second-line options (after benzodiazepine failure):
   • Levetiracetam 30 mg/kg IV (up to 4,500 mg) over 5-15 minutes
   • Alternative: Valproate or phenytoin/fosphenytoin
3. Position in treatment: Most studies used levetiracetam as second or third-line after benzodiazepines ± phenytoin/valproate 1

Important caveat: The evidence is primarily Class III (observational studies), and the guidelines note that "definite proof awaits prospective randomized controlled trials" 1. However, the consistency of findings across multiple studies and favorable safety profile support its use in clinical practice.

Other Emerging Off-Label Uses

Neonatal Seizures

• Limited evidence for refractory neonatal seizures despite off-label use 4, 5
• One RCT showed phenobarbital superior to levetiracetam (80% vs. 28% efficacy) as first-line treatment in term neonates 4
• May have role as second-line agent, but data insufficient
• Dosing: 40 mg/kg initial load, additional 20 mg/kg if needed 4

Seizure Prophylaxis (Not Recommended)

Levetiracetam should NOT be used for routine seizure prophylaxis in patients without prior seizures:

• Brain tumor patients: No evidence supporting prophylactic use regardless of tumor characteristics 6
• Post-neurosurgery: Perioperative prophylaxis "possibly not effective" in reducing seizures 6
• Critical care: While used for prophylaxis, only 54% achieve target levels with standard dosing; higher doses (750-1,000 mg bid) may be needed 7

Neuropsychiatric Conditions (Insufficient Evidence)

Preliminary data exists but cannot be recommended for routine clinical use 8, 9:

• Movement disorders (levodopa-induced dyskinesias in Parkinson's disease): Small open-label study showed improvement but 56% dropout rate due to somnolence 10
• Psychiatric disorders: anxiety, bipolar disorder, autism, Tourette's syndrome 9
• Neuropathic pain and headaches 8

Critical limitation: These uses are based on small case series and uncontrolled studies. The benefit-risk ratio must be carefully considered, especially given behavioral adverse effects in patients with psychiatric history 9.

Practical Considerations

Advantages Supporting Off-Label Use

• No hepatic metabolism (renal elimination only)
• No CYP450 interactions
• Low protein binding (reduces toxicity risk)
• Linear pharmacokinetics
• Ease of dosing without titration requirements 8, 5

Key Warnings

• Behavioral adverse effects may be more common in patients with psychiatric/neurobehavioral history 9
• Higher intubation rates observed with doses >40 mg/kg in some studies 11
• Underdosing common in ICU settings; therapeutic drug monitoring may be warranted 7

Bottom line: The primary evidence-supported off-label use is for benzodiazepine-refractory status epilepticus, where levetiracetam offers comparable efficacy to traditional agents with superior tolerability. Other off-label uses lack sufficient evidence for routine recommendation.